Insilico Medicine Surges 5% After Unveiling Novel Alzheimer's Targets in Landmark Study

Stock News

Sep 01

Insilico Medicine (03696) saw its share price climb more than 5% during Tuesday afternoon trading, buoyed by the announcement of a milestone research publication. As of the latest update, the stock was trading up 5.53% at HK$46.16, with turnover reaching HK$304 million.

The company announced that a landmark study has been published in the journal *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. The research, conducted in collaboration with scientists from the University of Oslo (UiO) and Akershus University Hospital (Ahus), was led by Dr. Sofie Lautrup and Professor Evandro Fei Fang. Using Insilico's proprietary AI-powered biology platform PandaOmics, combined with extensive experimental validation, the team identified novel molecular targets for Alzheimer's disease and other neurodegenerative conditions.

In related news, Insilico's Co-Chief Executive Officer and Chief Scientific Officer, Ren Feng, recently shared insights on the company's pipeline. He noted that there are currently ten drug candidates in clinical development. Among them, the idiopathic pulmonary fibrosis (IPF) project has entered Phase III clinical trials in China; if successful, it could represent a "DeepSeek moment" for the field of AI-driven drug discovery.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1186036617"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186036617\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186036617?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186036617","market":"nz","top_or_hot":-1,"title":"Insilico Medicine Surges 5% After Unveiling Novel Alzheimer's Targets in Landmark Study","media":"Stock News","content":"<p><b>Insilico Medicine (03696)</b> saw its share price climb more than 5% during Tuesday afternoon trading, buoyed by the announcement of a milestone research publication. As of the latest update, the stock was trading up 5.53% at HK$46.16, with turnover reaching HK$304 million.\n<br><br>\nThe company announced that a landmark study has been published in the journal *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. The research, conducted in collaboration with scientists from the University of Oslo (UiO) and Akershus University Hospital (Ahus), was led by Dr. Sofie Lautrup and Professor Evandro Fei Fang. Using Insilico's proprietary AI-powered biology platform PandaOmics, combined with extensive experimental validation, the team identified novel molecular targets for Alzheimer's disease and other neurodegenerative conditions.\n<br><br>\nIn related news, Insilico's Co-Chief Executive Officer and Chief Scientific Officer, Ren Feng, recently shared insights on the company's pipeline. He noted that there are currently ten drug candidates in clinical development. Among them, the idiopathic pulmonary fibrosis (IPF) project has entered Phase III clinical trials in China; if successful, it could represent a \"DeepSeek moment\" for the field of AI-driven drug discovery.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine Surges 5% After Unveiling Novel Alzheimer's Targets in Landmark Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine Surges 5% After Unveiling Novel Alzheimer's Targets in Landmark Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-01 14:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Insilico Medicine (03696)</b> saw its share price climb more than 5% during Tuesday afternoon trading, buoyed by the announcement of a milestone research publication. As of the latest update, the stock was trading up 5.53% at HK$46.16, with turnover reaching HK$304 million.\n<br><br>\nThe company announced that a landmark study has been published in the journal *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. The research, conducted in collaboration with scientists from the University of Oslo (UiO) and Akershus University Hospital (Ahus), was led by Dr. Sofie Lautrup and Professor Evandro Fei Fang. Using Insilico's proprietary AI-powered biology platform PandaOmics, combined with extensive experimental validation, the team identified novel molecular targets for Alzheimer's disease and other neurodegenerative conditions.\n<br><br>\nIn related news, Insilico's Co-Chief Executive Officer and Chief Scientific Officer, Ren Feng, recently shared insights on the company's pipeline. He noted that there are currently ten drug candidates in clinical development. Among them, the idiopathic pulmonary fibrosis (IPF) project has entered Phase III clinical trials in China; if successful, it could represent a \"DeepSeek moment\" for the field of AI-driven drug discovery.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1186036617","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186036617","pubTimestamp":1788242902,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Insilico Medicine (03696) saw its share price climb more than 5% during Tuesday afternoon trading, buoyed by the announcement of a milestone research publication. As of the latest update, the stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF","03696":"英矽智能","BK1141":"生命科学工具和服务"},"translate_title":"Insilico Medicine 在里程碑式研究中推出新型阿尔茨海默氏症靶点后股价飙升 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"03696":1,"KCAI":1},"content_text":"Insilico Medicine (03696) saw its share price climb more than 5% during Tuesday afternoon trading, buoyed by the announcement of a milestone research publication. As of the latest update, the stock was trading up 5.53% at HK$46.16, with turnover reaching HK$304 million.\n\nThe company announced that a landmark study has been published in the journal *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. The research, conducted in collaboration with scientists from the University of Oslo (UiO) and Akershus University Hospital (Ahus), was led by Dr. Sofie Lautrup and Professor Evandro Fei Fang. Using Insilico's proprietary AI-powered biology platform PandaOmics, combined with extensive experimental validation, the team identified novel molecular targets for Alzheimer's disease and other neurodegenerative conditions.\n\nIn related news, Insilico's Co-Chief Executive Officer and Chief Scientific Officer, Ren Feng, recently shared insights on the company's pipeline. He noted that there are currently ten drug candidates in clinical development. Among them, the idiopathic pulmonary fibrosis (IPF) project has entered Phase III clinical trials in China; if successful, it could represent a \"DeepSeek moment\" for the field of AI-driven drug discovery.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}